WEKO3
アイテム
{"_buckets": {"deposit": "c370f87c-5342-47cc-a115-3ba297fbc07c"}, "_deposit": {"created_by": 1, "id": "48131", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "48131"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00048131", "sets": ["1"]}, "author_link": ["483315", "483311", "483312", "483318", "483314", "483316", "483308", "483317", "483307", "483319", "483313", "483310", "483309"], "item_8_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2016-11", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "2", "bibliographicPageEnd": "293", "bibliographicPageStart": "288", "bibliographicVolumeNumber": "121", "bibliographic_titles": [{"bibliographic_title": "Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology"}]}]}, "item_8_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "BACKGROUND AND PURPOSE: A multi-institutional observational study (J-CROS1501PR) has been carried out to analyze outcomes of carbon-ion radiotherapy (CIRT) for patients with prostate cancer.\nPATIENTS AND METHODS: Data of the patients enrolled in prospective studies of following 3 CIRT institutions were analyzed: National Institute of Radiological Sciences (NIRS; Chiba, Japan), Gunma University Heavy Ion Medical Center (GHMC; Gunma, Japan), and Ion Beam Therapy Center, SAGA HIMAT Foundation (HIMAT; Saga, Japan). Endpoints of the clinical trial are biochemical recurrence-free survival (bRFS), overall survival (OS), cause-specific survival (CSS), local control rate (LCR), and acute/late adverse effects.\nRESULTS: A total of 2157 patients\u0027 data were collected from NIRS (n=1432), GHMC (n=515), and HIMAT (n=210). The number of patients in low-risk, intermediate-risk, and high-risk groups was 263 (12%), 679 (31%), and 1215 (56%), respectively. The five-year bRFS in low-risk, intermediate-risk, and high-risk patients was 92%, 89%, and 92%, respectively. The five-year CSS in low-risk, intermediate-risk, and high-risk patients was 100%, 100%, and 99%, respectively. The incidence of grade 2 late GU/GI toxicities was 4.6% and 0.4%, respectively, and the incidence of ⩾G3 toxicities were 0%.\nCONCLUSIONS: Favorable overall outcomes of CIRT for prostate cancer were suggested by the analysis of the first multi-institutional data.", "subitem_description_type": "Abstract"}]}, "item_8_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Elsevier Scientific Publishers"}]}, "item_8_relation_13": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "27836119", "subitem_relation_type_select": "PMID"}}]}, "item_8_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1016/j.radonc.2016.10.009", "subitem_relation_type_select": "DOI"}}]}, "item_8_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0167-8140", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Nomiya, Takuma"}], "nameIdentifiers": [{"nameIdentifier": "483307", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsuji, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "483308", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kawamura, Hidemasa"}], "nameIdentifiers": [{"nameIdentifier": "483309", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ohno, Tatsuya"}], "nameIdentifiers": [{"nameIdentifier": "483310", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Toyama, Shingo"}], "nameIdentifiers": [{"nameIdentifier": "483311", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shioyama, Yoshiyuki"}], "nameIdentifiers": [{"nameIdentifier": "483312", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakayama, Yuko"}], "nameIdentifiers": [{"nameIdentifier": "483313", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nemoto, Kenji"}], "nameIdentifiers": [{"nameIdentifier": "483314", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsujii, Hirohiko"}], "nameIdentifiers": [{"nameIdentifier": "483315", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kamada, Tadashi"}], "nameIdentifiers": [{"nameIdentifier": "483316", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "辻 比呂志", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "483317", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "辻井 博彦", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "483318", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "鎌田 正", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "483319", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "A multi-institutional analysis of prospective studies of carbon ion radiotherapy for prostate cancer: A report from the Japan Carbon ion Radiation Oncology Study Group (J-CROS).", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "A multi-institutional analysis of prospective studies of carbon ion radiotherapy for prostate cancer: A report from the Japan Carbon ion Radiation Oncology Study Group (J-CROS)."}]}, "item_type_id": "8", "owner": "1", "path": ["1"], "permalink_uri": "https://repo.qst.go.jp/records/48131", "pubdate": {"attribute_name": "公開日", "attribute_value": "2017-07-20"}, "publish_date": "2017-07-20", "publish_status": "0", "recid": "48131", "relation": {}, "relation_version_is_last": true, "title": ["A multi-institutional analysis of prospective studies of carbon ion radiotherapy for prostate cancer: A report from the Japan Carbon ion Radiation Oncology Study Group (J-CROS)."], "weko_shared_id": -1}
A multi-institutional analysis of prospective studies of carbon ion radiotherapy for prostate cancer: A report from the Japan Carbon ion Radiation Oncology Study Group (J-CROS).
https://repo.qst.go.jp/records/48131
https://repo.qst.go.jp/records/4813150eb92ac-1a73-4856-968e-6596e504f97f
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2017-07-20 | |||||
タイトル | ||||||
タイトル | A multi-institutional analysis of prospective studies of carbon ion radiotherapy for prostate cancer: A report from the Japan Carbon ion Radiation Oncology Study Group (J-CROS). | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Nomiya, Takuma
× Nomiya, Takuma× Tsuji, Hiroshi× Kawamura, Hidemasa× Ohno, Tatsuya× Toyama, Shingo× Shioyama, Yoshiyuki× Nakayama, Yuko× Nemoto, Kenji× Tsujii, Hirohiko× Kamada, Tadashi× 辻 比呂志× 辻井 博彦× 鎌田 正 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | BACKGROUND AND PURPOSE: A multi-institutional observational study (J-CROS1501PR) has been carried out to analyze outcomes of carbon-ion radiotherapy (CIRT) for patients with prostate cancer. PATIENTS AND METHODS: Data of the patients enrolled in prospective studies of following 3 CIRT institutions were analyzed: National Institute of Radiological Sciences (NIRS; Chiba, Japan), Gunma University Heavy Ion Medical Center (GHMC; Gunma, Japan), and Ion Beam Therapy Center, SAGA HIMAT Foundation (HIMAT; Saga, Japan). Endpoints of the clinical trial are biochemical recurrence-free survival (bRFS), overall survival (OS), cause-specific survival (CSS), local control rate (LCR), and acute/late adverse effects. RESULTS: A total of 2157 patients' data were collected from NIRS (n=1432), GHMC (n=515), and HIMAT (n=210). The number of patients in low-risk, intermediate-risk, and high-risk groups was 263 (12%), 679 (31%), and 1215 (56%), respectively. The five-year bRFS in low-risk, intermediate-risk, and high-risk patients was 92%, 89%, and 92%, respectively. The five-year CSS in low-risk, intermediate-risk, and high-risk patients was 100%, 100%, and 99%, respectively. The incidence of grade 2 late GU/GI toxicities was 4.6% and 0.4%, respectively, and the incidence of ⩾G3 toxicities were 0%. CONCLUSIONS: Favorable overall outcomes of CIRT for prostate cancer were suggested by the analysis of the first multi-institutional data. |
|||||
書誌情報 |
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 巻 121, 号 2, p. 288-293, 発行日 2016-11 |
|||||
出版者 | ||||||
出版者 | Elsevier Scientific Publishers | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0167-8140 | |||||
PubMed番号 | ||||||
識別子タイプ | PMID | |||||
関連識別子 | 27836119 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1016/j.radonc.2016.10.009 |